Patents Assigned to Janssen Pharmaceuticals
-
Patent number: 11958889Abstract: Liposomes containing tau peptides, preferably phosphorylated tau peptides, and conjugates containing tau peptides, preferably phosphorylated tau peptides, conjugated to an immunogenic carrier are described. Pharmaceutical compositions and uses of the liposomes and/or conjugates for treating or preventing a neurodegenerative disease or disorder, such as Alzheimer's Disease, are also described.Type: GrantFiled: October 24, 2018Date of Patent: April 16, 2024Assignees: Janssen Pharmaceuticals, Inc., AC Immune SAInventors: Elizabeth Anne Ramsburg, Donata de Marco, Charlotte Sadaka, Jaap Goudsmit, Andreas Muhs, Maria Pihlgren Bosch, Marija Vukicevic Verhille, David Hickman, Nicolas Piot, Saroj Raj Ghimire
-
Patent number: 11918791Abstract: A grip accessory for a manual injection device comprises a housing having a generally hollow body for supporting a manual injection device therein. The housing comprises a distal portion comprising a first opening into which a manual injection device can be inserted, a proximal portion comprising a second opening through which a needle of the manual injection device is extendable, the proximal portion comprising a skin contacting surface at a proximal end of the device. An intermediate portion extends between the proximal and distal portions and guide means is provided on an interior surface of the distal portion for guiding a plunger rod of an injection device during delivery of an injection.Type: GrantFiled: May 29, 2018Date of Patent: March 5, 2024Assignee: Janssen Pharmaceuticals, Inc.Inventors: James McLusky, Nick Foley, Jimmy Mower, Ian Scrimgeour, Michael Cannamela, Peter Krulevitch, Kui Liu
-
Patent number: 11915608Abstract: An injection device and an injection device trainer for training a user to use an injection device. Each one of the injection device and the injection device trainer can include: a body portion; an actuator positioned towards a proximal end of the body portion, the actuator moveable from a proximal position to a distal position; a shield positioned towards a distal end of the body portion, the shield moveable between: an initial position; an extended position that is more distal relative to the body portion than the initial position; and a connector that connects the actuator to the shield such that movement of the actuator from the distal position towards the proximal position pulls the shield from the extended position to the initial position.Type: GrantFiled: September 27, 2019Date of Patent: February 27, 2024Assignee: Janssen Pharmaceuticals, Inc.Inventor: Hung Mach
-
Patent number: 11844766Abstract: Compositions and methods for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) are described. In particular, multivalent vaccines containing O-antigen polysaccharide covalently bound to an exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein that can withstand multiple environmental stresses are describe.Type: GrantFiled: May 12, 2021Date of Patent: December 19, 2023Assignee: JANSSEN PHARMACEUTICALS, INC.Inventors: Olga Labovitiadi, Wouter Frank Tonnis, Francesco Doro, Janik Adriaansen
-
Patent number: 11845939Abstract: The present disclosure generally relates to nucleic acid molecules for use in regulating gene expression. Disclosed herein include nucleic acid molecules containing one or more structural elements of the viral capsid enhancer operably linked to a coding sequence of a gene of interest. In some embodiments, the viral capsid enhancer comprises a Downstream Loop (DLP) from a viral capsid protein, or a variant of the DLP.Type: GrantFiled: December 4, 2017Date of Patent: December 19, 2023Assignee: Janssen Pharmaceuticals, Inc.Inventors: Kurt Iver Kamrud, Maung Nyan Win, Nathaniel Stephen Wang, Jason L. DeHart
-
Patent number: 11827602Abstract: The present invention relates to mono- or di-substituted indole compounds, methods to prevent or treat dengue viral infections by using the compounds and also relates to use of the compounds as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.Type: GrantFiled: December 31, 2020Date of Patent: November 28, 2023Assignees: Janssen Pharmaceuticals, Inc., Katholieke Universiteit LeuvenInventors: Bart Rudolf Romanie Kesteleyn, Jean-François Bonfanti, Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson, Dorothée Alice Marie-Eve Bardiot, Arnaud Didier M Marchand
-
Patent number: 11826416Abstract: The present disclosure generally relates to the use of different self-amplifying RNA molecules to enhance immune responses, for example immune responses following prophylactic vaccination or therapeutic administration. Some embodiments relate to compositions and methods for inducing an immune response in a subject using prime-boost immunization regimens.Type: GrantFiled: July 7, 2021Date of Patent: November 28, 2023Assignee: Janssen Pharmaceuticals, Inc.Inventors: Kurt Iver Kamrud, Nathaniel Stephen Wang, Parinaz Aliahmad, Jason L. Dehart
-
Patent number: 11795149Abstract: The present invention concerns substituted indoline derivatives, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.Type: GrantFiled: June 16, 2022Date of Patent: October 24, 2023Assignees: Janssen Pharmaceuticals, Inc., Katholieke Universiteit LeuvenInventors: Jean-François Bonfanti, Bart Rudolf Romanie Kesteleyn, Dorothée Alice Marie-Eve Bardiot, Arnaud Didier M Marchand, Erwin Coesemans, Jérôme Michel Claude Fortin, Guillaume Jean Maurice Mercey, Pierre Jean-Marie Bernard Raboisson
-
Patent number: 11786665Abstract: A grip accessory for a manual injection device comprises a housing comprising a generally hollow body configured to support a manual injection device therein. The housing comprises a distal portion comprising a first opening into which a manual injection device can be inserted, a proximal portion having a second opening through which the needle of the manual injection device extends. The proximal portion comprises a skin contacting surface at a proximal end of the device that can be placed against an injection site. An intermediate portion extends between the proximal and distal portions.Type: GrantFiled: May 29, 2018Date of Patent: October 17, 2023Assignee: JANSSEN PHARMACEUTICALS, INC.Inventors: James McLusky, Nick Foley, Jimmy Mower, Ian Scrimgeour, Michael Cannamela, Peter Krulevitch, Kui Liu
-
Publication number: 20230321355Abstract: An injection device comprises a housing having a proximal end, a distal end and a longitudinal axis extending therebetween. The housing has a hand grip portion with a non-rotationally symmetric cross section about the longitudinal axis of the device at the proximal end of the housing.Type: ApplicationFiled: June 13, 2023Publication date: October 12, 2023Applicant: Janssen Pharmaceuticals, Inc.Inventors: Peter Krulevitch, Michael Cannamela, Nick Foley, James McLusky, Jimmy Mower, Scott Martin, James Glencross
-
Patent number: 11773126Abstract: Disclosed herein are compounds of the Formula (I) and pharmaceutically acceptable salts thereof: (I) where the variables in Formula (I) are described herein. Methods of synthesizing such compounds and methods of using them to treat diseases and/or conditions such as a Picornaviridae, Flaviviridae, Filoviridae, Pneumoviridae and/or Coronaviridae viral infections are also disclosed.Type: GrantFiled: August 26, 2021Date of Patent: October 3, 2023Assignee: Janssen Pharmaceuticals, Inc.Inventors: Leonid Beigelman, Jerome Deval, Marija Prhavc
-
Patent number: 11724035Abstract: An injection device comprises a housing having a proximal end, a distal end and a longitudinal axis extending therebetween. The housing has a hand grip portion with a non-rotationally symmetric cross section about the longitudinal axis of the device at the proximal end of the housing.Type: GrantFiled: July 28, 2020Date of Patent: August 15, 2023Assignee: Janssen Pharmaceuticals, Inc.Inventors: Peter Krulevitch, Michael Cannamela, Nick Foley, James McLusky, Jimmy Mower, Scott Martin, James Glencross
-
Patent number: 11725028Abstract: Polypeptides comprising a FimH lectin domain comprising at least one an amino acid mutation that causes the FimH lectin domain to be in the low affinity conformation for mannose are described. Pharmaceutical compositions which comprise such polypeptides and methods of stimulating an immune response in a subject in need thereof by administration of the polypeptide are further described.Type: GrantFiled: January 11, 2022Date of Patent: August 15, 2023Assignee: JANSSEN PHARMACEUTICALS, INC.Inventors: Jan Grijpstra, Marleen Eveline Weerdenburg, Jeroen Geurtsen, Cristhina Kellen Fae, Jakob Louris Feitsma
-
Patent number: 11707440Abstract: The present invention provides methods of maintaining stable remission or stable response achieved by a patient with depression following administration of a therapeutically effective amount of esketamine during an initial administration phase, comprising continuing administration of a therapeutically effective amount of esketamine for at least five months during a subsequent administration phase. The present invention also provides methods for the long term treatment of depression in a patient, comprising administering to the patient in need of the treatment a clinically proven safe and clinically proven effective therapeutically effective amount of esketamine for at least six months. In some embodiments, the depression is major depressive disorder or treatment resistant depression.Type: GrantFiled: December 18, 2018Date of Patent: July 25, 2023Assignee: Janssen Pharmaceuticals, Inc.Inventors: Wayne Drevets, Honglan Li, David Wood Hough, Jaskaran Singh, Ewa Wajs
-
Patent number: 11701475Abstract: An accessory for an injection device having a safety shield and at least one flange adapted to allow a user to grip the injection device and a syringe sheath moveable relative to the at least one flange from a pre-injection position to a locked-out position. The accessory comprises a body portion comprising a recess adapted to receive the safety shield of the injection device and a slot adapted to receive the at least one flange of the injection device.Type: GrantFiled: December 17, 2019Date of Patent: July 18, 2023Assignee: Janssen Pharmaceuticals, Inc.Inventors: James D. McLusky, Nick Foley, Gavin F. McDougall, Roy A. Crerar, James N. Mower
-
Patent number: 11702387Abstract: The present invention concerns substituted indoline derivatives, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.Type: GrantFiled: May 28, 2021Date of Patent: July 18, 2023Assignees: Janssen Pharmaceuticals, Inc., Katholieke Universiteit LeuvenInventors: Jean-François Bonfanti, Bart Rudolf Romanie Kesteleyn, Dorothée Alice Marie-Eve Bardiot, Arnaud Didier M Marchand, Erwin Coesemans, Benoît Christian Albert Ghislain De Boeck, Pierre Jean-Marie Bernard Raboisson
-
Patent number: 11684576Abstract: Methods for inducing anti-phosphorylated Tau antibodies without inducing a severe adverse event in humans are described. The methods include administering to the subject an effective amount of liposomes including a toll-like receptor 4 agonist and a Tau phosphopeptide presented on the surface of the liposome.Type: GrantFiled: February 7, 2020Date of Patent: June 27, 2023Assignees: AC Immune SA, Janssen Pharmaceuticals, Inc.Inventors: Andrea Pfeifer, Andreas Muhs, Maria Pihlgren Bosch, Marija Vukicevic Verhille, Nicolas Piot, Saroj Raj Ghimire, Elizabeth Anne Ramsburg, Donata De Marco, Charlotte Sadaka
-
Patent number: 11649283Abstract: The invention provides antagonistic and agonistic anti-human VISTA antibodies and antibody fragments. These antagonist antibodies and antibody fragments may be used to inhibit or block VISTA's suppressive effects on T cell immunity and thereby promote T cell immunity. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These antagonist antibodies and antibody fragments are especially useful in the treatment of cancer and infectious conditions. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.Type: GrantFiled: April 14, 2017Date of Patent: May 16, 2023Assignees: IMMUNEXT, INC., JANSSEN PHARMACEUTICALS, INC.Inventors: Michael Molloy, Jay Rothstein, Dov Pechenick, Linda Snyder, Gordon Powers
-
Patent number: 11607216Abstract: In general, adaptive responses from smart packaging of drug delivery absorbable adjuncts and methods of using smart packaging of drug delivery absorbable adjuncts are provided.Type: GrantFiled: October 13, 2020Date of Patent: March 21, 2023Assignee: Janssen Pharmaceuticals, Inc.Inventors: Peter Krulevitch, Francesco N. Albertini, Jason L. Harris, Michael J. Vendely, Gregory J. Bakos, Frederick E. Shelton, IV, Michael Hutchinson
-
Patent number: RE49517Abstract: The invention relates to pyrazole derivatives which are NMDA NR2B receptor inhibitors, useful in treating central nervous system diseases.Type: GrantFiled: December 17, 2020Date of Patent: May 2, 2023Assignee: JANSSEN PHARMACEUTICALS, INC.Inventors: Rudolf Schindler, Hans-Joachim Lankau, Norbert Höfgen, Christian Grunwald, Ute Egerland, Barbara Langen, Rita Dost, Thorsten Hage, Simon Ward